Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenteritis | 9 | 2025 | 26 | 3.510 |
Why?
|
| Hepatitis C, Chronic | 24 | 2024 | 65 | 3.270 |
Why?
|
| Antiviral Agents | 16 | 2024 | 95 | 1.560 |
Why?
|
| Hepatitis B, Chronic | 10 | 2023 | 27 | 1.500 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2025 | 535 | 1.350 |
Why?
|
| Hepatitis C | 8 | 2023 | 65 | 1.340 |
Why?
|
| Rotavirus | 4 | 2022 | 18 | 1.250 |
Why?
|
| Caliciviridae Infections | 3 | 2025 | 5 | 1.210 |
Why?
|
| Liver Cirrhosis | 11 | 2024 | 35 | 1.160 |
Why?
|
| Humans | 57 | 2025 | 17762 | 0.900 |
Why?
|
| Cost of Illness | 1 | 2024 | 92 | 0.870 |
Why?
|
| United States | 29 | 2025 | 4003 | 0.860 |
Why?
|
| Child | 16 | 2025 | 2491 | 0.830 |
Why?
|
| Middle Aged | 37 | 2025 | 7988 | 0.820 |
Why?
|
| Herpes Zoster | 1 | 2024 | 82 | 0.810 |
Why?
|
| Adult | 37 | 2025 | 7678 | 0.800 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2023 | 26 | 0.800 |
Why?
|
| Health Care Costs | 1 | 2024 | 229 | 0.780 |
Why?
|
| Male | 39 | 2025 | 10106 | 0.770 |
Why?
|
| Dementia | 1 | 2024 | 112 | 0.770 |
Why?
|
| Young Adult | 21 | 2025 | 2461 | 0.770 |
Why?
|
| Infant | 11 | 2025 | 1192 | 0.720 |
Why?
|
| Sustained Virologic Response | 6 | 2023 | 17 | 0.710 |
Why?
|
| Female | 39 | 2025 | 12740 | 0.690 |
Why?
|
| Epidemiological Monitoring | 2 | 2018 | 25 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2025 | 390 | 0.640 |
Why?
|
| Adolescent | 18 | 2025 | 3685 | 0.630 |
Why?
|
| Aged | 26 | 2025 | 6150 | 0.620 |
Why?
|
| Norovirus | 3 | 2025 | 5 | 0.610 |
Why?
|
| Rotavirus Vaccines | 3 | 2024 | 52 | 0.610 |
Why?
|
| Cohort Studies | 18 | 2025 | 2586 | 0.610 |
Why?
|
| Whooping Cough | 2 | 2018 | 66 | 0.590 |
Why?
|
| Child, Preschool | 9 | 2025 | 1419 | 0.580 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 40 | 0.530 |
Why?
|
| Hepacivirus | 10 | 2024 | 52 | 0.520 |
Why?
|
| Incidence | 7 | 2025 | 1266 | 0.490 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 34 | 0.470 |
Why?
|
| Vaccination | 5 | 2025 | 655 | 0.470 |
Why?
|
| Influenza Vaccines | 2 | 2024 | 273 | 0.470 |
Why?
|
| Hepatitis B | 3 | 2023 | 42 | 0.460 |
Why?
|
| Immunization, Secondary | 2 | 2013 | 57 | 0.460 |
Why?
|
| Rotavirus Infections | 3 | 2022 | 31 | 0.430 |
Why?
|
| Biomarkers | 5 | 2017 | 303 | 0.400 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 113 | 0.390 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 125 | 0.390 |
Why?
|
| Retrospective Studies | 9 | 2024 | 2461 | 0.390 |
Why?
|
| Coinfection | 3 | 2023 | 30 | 0.380 |
Why?
|
| Time Factors | 10 | 2019 | 1093 | 0.370 |
Why?
|
| Feces | 2 | 2022 | 80 | 0.340 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 19 | 0.290 |
Why?
|
| Oregon | 6 | 2025 | 180 | 0.280 |
Why?
|
| African Americans | 5 | 2020 | 472 | 0.270 |
Why?
|
| Risk Assessment | 5 | 2023 | 1101 | 0.270 |
Why?
|
| Diarrhea | 2 | 2023 | 13 | 0.260 |
Why?
|
| Influenza, Human | 2 | 2024 | 265 | 0.250 |
Why?
|
| Health Status | 2 | 2020 | 298 | 0.250 |
Why?
|
| Risk Factors | 9 | 2020 | 3356 | 0.250 |
Why?
|
| Metapneumovirus | 1 | 2025 | 4 | 0.250 |
Why?
|
| Paramyxoviridae Infections | 1 | 2025 | 5 | 0.250 |
Why?
|
| Hepatitis B virus | 3 | 2023 | 20 | 0.240 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2025 | 8 | 0.240 |
Why?
|
| Seasons | 1 | 2025 | 105 | 0.240 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2025 | 21 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 25 | 0.240 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 29 | 0.240 |
Why?
|
| History, 21st Century | 1 | 2024 | 24 | 0.230 |
Why?
|
| Aminoisobutyric Acids | 1 | 2024 | 2 | 0.230 |
Why?
|
| Cyclopropanes | 1 | 2024 | 2 | 0.230 |
Why?
|
| Lactams, Macrocyclic | 1 | 2024 | 2 | 0.230 |
Why?
|
| Leucine | 1 | 2024 | 3 | 0.230 |
Why?
|
| Benzimidazoles | 1 | 2024 | 6 | 0.230 |
Why?
|
| Proline | 1 | 2024 | 5 | 0.230 |
Why?
|
| Sulfonamides | 1 | 2024 | 14 | 0.230 |
Why?
|
| Acute Disease | 1 | 2024 | 142 | 0.220 |
Why?
|
| Herpesvirus 3, Human | 1 | 2024 | 44 | 0.220 |
Why?
|
| HIV Infections | 2 | 2015 | 696 | 0.210 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 10 | 0.210 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 10 | 0.210 |
Why?
|
| Age Factors | 5 | 2019 | 918 | 0.210 |
Why?
|
| Prospective Studies | 7 | 2023 | 1279 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 146 | 0.210 |
Why?
|
| Quality of Life | 3 | 2023 | 510 | 0.210 |
Why?
|
| Ribavirin | 2 | 2019 | 8 | 0.200 |
Why?
|
| Liver | 3 | 2017 | 32 | 0.200 |
Why?
|
| Aspartate Aminotransferases | 3 | 2020 | 13 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 382 | 0.200 |
Why?
|
| Alanine Transaminase | 3 | 2020 | 21 | 0.190 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 1923 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 755 | 0.190 |
Why?
|
| Population Surveillance | 1 | 2003 | 264 | 0.190 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 292 | 0.190 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2021 | 1 | 0.190 |
Why?
|
| Washington | 4 | 2025 | 382 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 455 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1213 | 0.180 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 2 | 0.170 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 2 | 0.170 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 2 | 0.170 |
Why?
|
| International Classification of Diseases | 2 | 2017 | 85 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 67 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 172 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2024 | 1260 | 0.160 |
Why?
|
| Logistic Models | 3 | 2019 | 927 | 0.160 |
Why?
|
| RNA, Viral | 2 | 2019 | 64 | 0.160 |
Why?
|
| Prevalence | 5 | 2023 | 886 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2020 | 141 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 6 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2018 | 114 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 48 | 0.150 |
Why?
|
| Mental Health | 2 | 2020 | 166 | 0.150 |
Why?
|
| Data Mining | 1 | 2017 | 17 | 0.150 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 415 | 0.140 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2018 | 88 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 88 | 0.140 |
Why?
|
| Viral Load | 1 | 2017 | 135 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1120 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 13 | 0.130 |
Why?
|
| Alcoholism | 2 | 2017 | 348 | 0.130 |
Why?
|
| Gastroenterology | 1 | 2016 | 19 | 0.130 |
Why?
|
| Serum | 1 | 2016 | 3 | 0.130 |
Why?
|
| Data Collection | 2 | 2014 | 256 | 0.130 |
Why?
|
| Liver Failure | 1 | 2015 | 1 | 0.130 |
Why?
|
| Depression | 2 | 2017 | 505 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2016 | 169 | 0.120 |
Why?
|
| Pertussis Vaccine | 1 | 2015 | 14 | 0.120 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 1 | 0.120 |
Why?
|
| Hepatitis A | 1 | 2014 | 10 | 0.120 |
Why?
|
| Hepatitis C Antibodies | 1 | 2014 | 3 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cause of Death | 3 | 2021 | 181 | 0.120 |
Why?
|
| Off-Label Use | 1 | 2013 | 14 | 0.110 |
Why?
|
| European Continental Ancestry Group | 3 | 2020 | 529 | 0.110 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 32 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2013 | 128 | 0.110 |
Why?
|
| Veterans | 1 | 2014 | 143 | 0.100 |
Why?
|
| Asian Americans | 3 | 2020 | 176 | 0.100 |
Why?
|
| Electronic Health Records | 2 | 2017 | 697 | 0.100 |
Why?
|
| Platelet Count | 3 | 2017 | 9 | 0.100 |
Why?
|
| Smoking | 1 | 2015 | 483 | 0.100 |
Why?
|
| Health Maintenance Organizations | 1 | 2013 | 417 | 0.100 |
Why?
|
| Hospitalization | 3 | 2022 | 808 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 568 | 0.090 |
Why?
|
| Biopsy | 3 | 2015 | 75 | 0.090 |
Why?
|
| Vaccines, Inactivated | 1 | 2010 | 67 | 0.090 |
Why?
|
| Meningitis, Meningococcal | 1 | 2010 | 7 | 0.090 |
Why?
|
| Adenovirus Infections, Human | 1 | 2009 | 1 | 0.080 |
Why?
|
| Adenoviruses, Human | 1 | 2009 | 1 | 0.080 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2014 | 33 | 0.080 |
Why?
|
| Health Surveys | 2 | 2020 | 260 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 1321 | 0.070 |
Why?
|
| Fever | 2 | 2023 | 55 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2020 | 671 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 710 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 597 | 0.070 |
Why?
|
| Social Support | 2 | 2020 | 206 | 0.060 |
Why?
|
| Hispanic Americans | 2 | 2020 | 404 | 0.060 |
Why?
|
| Climate | 1 | 2025 | 4 | 0.060 |
Why?
|
| Humidity | 1 | 2025 | 3 | 0.060 |
Why?
|
| Temperature | 1 | 2025 | 19 | 0.060 |
Why?
|
| Critical Care | 2 | 2020 | 71 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 354 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 630 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2016 | 183 | 0.060 |
Why?
|
| Sex Factors | 2 | 2017 | 644 | 0.060 |
Why?
|
| Disease Progression | 2 | 2015 | 264 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2024 | 2 | 0.060 |
Why?
|
| Pruritus | 1 | 2023 | 3 | 0.060 |
Why?
|
| Quinoxalines | 1 | 2024 | 12 | 0.060 |
Why?
|
| Fatigue | 1 | 2023 | 34 | 0.060 |
Why?
|
| Genotype | 1 | 2024 | 227 | 0.050 |
Why?
|
| Heterosexuality | 1 | 2003 | 9 | 0.050 |
Why?
|
| Homosexuality | 1 | 2003 | 5 | 0.050 |
Why?
|
| Michigan | 1 | 2003 | 26 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 13 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2003 | 37 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 63 | 0.050 |
Why?
|
| Women's Health | 1 | 2003 | 201 | 0.050 |
Why?
|
| Medical Records | 2 | 2014 | 100 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 231 | 0.050 |
Why?
|
| Germinal Center | 1 | 2021 | 1 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 4 | 0.050 |
Why?
|
| Survivorship | 1 | 2021 | 9 | 0.050 |
Why?
|
| Vaccines, Attenuated | 1 | 2021 | 45 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2020 | 7 | 0.040 |
Why?
|
| Unemployment | 1 | 2020 | 12 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 30 | 0.040 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 35 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 181 | 0.040 |
Why?
|
| Pregnancy | 1 | 2025 | 1524 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 260 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2021 | 247 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 105 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 114 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 6 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 42 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 203 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Clinical Enzyme Tests | 1 | 2017 | 1 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2017 | 2 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 287 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 216 | 0.040 |
Why?
|
| Fibrosis | 1 | 2017 | 7 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 129 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2017 | 190 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 246 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 343 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 381 | 0.030 |
Why?
|
| Medicine | 1 | 2016 | 22 | 0.030 |
Why?
|
| Mamastrovirus | 1 | 2016 | 1 | 0.030 |
Why?
|
| Astroviridae Infections | 1 | 2016 | 1 | 0.030 |
Why?
|
| Sapovirus | 1 | 2016 | 1 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 35 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 609 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 135 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 105 | 0.030 |
Why?
|
| Medicare | 1 | 2016 | 205 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 215 | 0.030 |
Why?
|
| Medicaid | 1 | 2016 | 190 | 0.030 |
Why?
|
| Hepatitis A Antibodies | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 12 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 80 | 0.030 |
Why?
|
| Hepatitis A Vaccines | 1 | 2014 | 14 | 0.030 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 43 | 0.030 |
Why?
|
| Pathology | 1 | 2014 | 4 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 373 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 304 | 0.030 |
Why?
|
| California | 1 | 2020 | 2326 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 719 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 769 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 855 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2016 | 485 | 0.030 |
Why?
|
| Research Design | 1 | 2014 | 376 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 487 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 434 | 0.020 |
Why?
|
| Serotyping | 1 | 2009 | 3 | 0.020 |
Why?
|
| Oxygen | 1 | 2009 | 16 | 0.020 |
Why?
|
| Cross Infection | 1 | 2009 | 27 | 0.020 |
Why?
|
Concepts
(242)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(9)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->